Invention Grant
- Patent Title: Substituted pyrrolidine compound and use thereof
-
Application No.: US16491811Application Date: 2018-03-07
-
Publication No.: US11059780B2Publication Date: 2021-07-13
- Inventor: Masaki Daini , Yuhei Miyanohana , Satoshi Mikami , Yuichi Kajita , Masaki Ogino , Tatsuki Koike , Kohei Takeuchi
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JPJP2017-044249 20170308
- International Application: PCT/JP2018/008811 WO 20180307
- International Announcement: WO2018/164191 WO 20180913
- Main IPC: C07D207/12
- IPC: C07D207/12 ; C07D405/12 ; C07D403/12 ; C07D405/14 ; C07D401/14 ; C07D417/14 ; C07D403/14 ; C07D493/08 ; C07D487/10 ; C07D498/10 ; C07D471/04 ; C07D413/12 ; C07D491/107 ; C07D487/08
Abstract:
The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Information query
